CMET-18. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES

BACKGROUND: Immunotherapy is increasingly used in patients with non-small cell lung cancer brain metastases (NSCLCBM). KRAS mutations are associated with worse prognosis and there is no FDA approved targeted therapy. KRAS mutations are associated with increased expression of PD-L1. We evaluated the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Lauko, Adam, Ali, Assad, Sagar, Soumya, Barnett, Addison, Li, Hong, Chao, Samuel, Stevens, Glen, Pennell, Nathan, Peereboom, David, Yu, Jennifer, Murphy, Erin, Angelov, Lilyana, Funchain, Pauline, Mohammadi, Alireza, Suh, John, Barnett, Gene, Ahluwalia, Manmeet
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
CNS Metastasis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847893/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.219
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller